Paper
Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs.
Published 2014 · Lingzi Zhang, P. Zhan, Xuwang Chen
Bioorganic & medicinal chemistry
Q2 SJR score
21
Citations
0
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
In Vitro StudyStudy Snapshot
Novel N-arylmethyl substituted piperidine-linked aniline derivatives show moderate to potent anti-HIV activity, with compound 5a6 being the most potent and selective inhibitor.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
HIV‐1 NNRTIs: structural diversity, pharmacophore similarity, and impliations for drug design
HIV-1 NNRTIs have structural diversity and pharmacophore similarity, which can aid in the discovery and optimization of novel, highly potent anti-AIDS drugs.
2013·185citations·P. Zhan et al.·Medicinal Research Reviews
Medicinal Research Reviews
Recent advances of diaryl ether family as HIV-1 non-nucleoside reverse transcriptase inhibitors.
Diaryl ether family shows promise as a second-generation HIV-1 NNRTI, with clinical candidate MK-4965 advanced into phase II clinical trials, offering valuable avenues for designing other novel anti-HIV drug candidates.
2013·11citations·Xuwang Chen et al.·Current pharmaceutical design
Current pharmaceutical design
Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.
Novel 4-substituted 1,5-diarylanilines show high potency against HIV-1 and drug-resistant strains, warranting further development as potential anti-AIDS clinical trial candidates.
2012·54citations·Lian-Qi Sun et al.·Journal of medicinal chemistry
Journal of medicinal chemistry
Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.
Piperidine-linked amino-triazine derivatives show excellent anti-HIV activity with low nanomolar concentrations and high activity against K103N/Y181C resistant mutant strains.
2012·59citations·Xuwang Chen et al.·Bioorganic & medicinal chemistry
Bioorganic & medicinal chemistry
Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
Piperidine-substituted triazine derivatives show promising anti-HIV activity, with better activity against wild-type HIV-1 and resistant mutant strains than current treatments.
2012·43citations·Xuwang Chen et al.·European journal of medicinal chemistry
European journal of medicinal chemistry
Citations
Medicinal chemistry perspectives on the development of piperazine-containing HIV-1 inhibitors.
Piperazine-containing HIV-1 inhibitors show promising enhancement in anti-HIV activity, offering new avenues for developing effective antiretroviral targets and eliminating latent reservoirs.
2024·6citations·Christiana Abimbola Salubi et al.·Bioorganic & medicinal chemistry
Bioorganic & medicinal chemistry
Combination of 2D and 3D-QSAR studies on DAPY and DANA derivatives as potent HIV-1 NNRTIs
Combining 2D and 3D-QSAR models, we can predict the design of novel anti-HIV agents by analyzing 3D contour maps and 2D molecular fragments.
2022·5citations·Xiao Ding et al.·Journal of Molecular Structure
Journal of Molecular Structure
Recent progress in HIV-1 inhibitors targeting the entrance channel of HIV-1 non-nucleoside reverse transcriptase inhibitor binding pocket.
Recent progress in HIV-1 inhibitors targeting the entrance channel of HIV-1 NNIBP has led to the discovery of promising compounds with excellent antiviral activities and physicochemical properties.
2019·17citations·Shuang‐Xi Gu et al.·European journal of medicinal chemistry
European journal of medicinal chemistry
Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.
11c, a diarylpyrimidine-typed HIV-1 NNRTI, shows potent anti-HIV-1 activity against wild-type and E138K mutant viruses with improved water solubility and favorable safety profiles, making it a promising lead for further structural optimization.
2019·66citations·Boshi Huang et al.·Journal of medicinal chemistry
Journal of medicinal chemistry
Recent Advances in the Design and Development of Non‐nucleoside Reverse Transcriptase Inhibitor Scaffolds
Recent advances in designing and developing new potent NNRTIs with improved safety and activity against drug-resistant HIV strains have significantly advanced the field from 2013 to 2018.
2018·21citations·Pouria Shirvani et al.·ChemMedChem
ChemMedChem